A special issue on Nursing: Current Scenario and Future Development - Articles are invited.

Investigating soluble thrombomodulin (sTM) as a predictor for major adverse cardiac events (MACE) after PCI in patients without current risk factors

Authors: Nozar Givtaj, Hossain Ali Bassiri and Hooman Bakhshandeh

Int J Med Res Health Sci.17-20 | pdf PDF Full Text

Prediction of major adverse cardiac events (MACE) has recently been a focus of biomedical researches.
Identification of the predictors can be useful to select at risk patients for preventive treatment and healthy-life
maintenance. The aim of this study was to evaluate the role of soluble thrombomodulin (sTM) to predict the
development of MACE after PCI and stent placement. A total of 140 patients (aged 40-70 Years) undergoing
percutaneous coronary intervention (PCI) and stent placement who’s had inclusion craiteria were enroled.
Personal information and medical history were recorded in a form. Blood samples were collected 24 hours after
PCI and serum level of sTM was measured. Patients were followed up for 18 months. Coronary angiography was
done for patients with chest pain or positive results of non- invasive tests. End point of the study was MACE
including death, MI, early or late stent Thrombosis, Target vessel revascularization (TVR) and target lesion
revascularization (TLR). mean age of patients was 55.61 and most of them were male (65%)-most common risk
factor was dislipidemia (46%) and LAD was most common vessel (69%)- in follow up time coronary angiography
was done for 39 patients That 29 of Them (20.7) had MACE 13 target. Lesion restenosis, 10 target vessel restenosis,
2 MI and 3 Thrombosis and one patient dead. There was signification association between, Reference vessels
diameter with MACE (2.56 ± 0.25 VS 3.28 ± 0.39 mm P < 0/001). Mean Blood level of sTM in patients who had
MACE was lower than mean sTM in other patient but there was not statistically significant (13.99 ±2.65 VS 15.11
±3.25 ng/ml P=0.070). But among patients who had no t current risk factors, mean blood level of sTM in cases with
MACE was significantly lower than mean of sTM in cases without MACE.(11.84 ± 1.92 VS 16.46 ± 3.38 ng /ml P=
0.019 ) but only 4 patients were in first group ( patients without current risk factors who had MACE). Despite the
result of our study indicate that in patients who had not current risk. Factors, development of MACE after PCI and
stent placement associate with low blood level of sTM but introduce of sTM as a predictor, need to supplementary
investigations with more number of the patients

International Journal of Medical Research & Health Sciences © 2012-16 [Last updated: July 2016] by AspiringDigital